Jefferson Adams is a freelance writer living in San Francisco. His poems, essays and photographs have appeared in Antioch Review, Blue Mesa Review, CALIBAN, Hayden's Ferry Review, Huffington Post, the Mississippi Review, and Slate among others.
He is a member of both the National Writers Union, the International Federation of Journalists, and covers San Francisco Health News for Examiner.com.
Celiac.com 04/18/2012 - Biopharmaceutical development company, BioLineRx, has announced results from pre-clinical trials which show that their compound, BL-7010, an orally available treatment for celiac disease, reduces the toxic effects of gluten in patients with celiac disease.
The findings, which appear in the February issue of Gastroenterology, show that BL-7010, which was previously labeled P(HEMA-co-SS, lowers gluten toxicity by reducing the body's digestion of wheat gluten.
The findings also show that BL-7010 also improves the immune response to gluten in rodents, as well as preventing gluten-induced pathological damage to the small intestine.
Furthermore, they note that BL-7010 is not absorbed systemically, indicating that its gluten-neutralizing effects are likely safe. These data demonstrate BL-7010's therapeutic potential for reducing or blocking gluten-induced disorders in humans with celiac disease.
Because it can be difficult to maintain a life-long, strict, gluten-free diet, the fact that BL-7010 may attenuate the immune response to gluten and reduce subsequent damage to the small intestine, suggests that this drug, or others like it may be useful in improving quality of life for millions of celiac disease patients.